6,678 trials
Relapsing-remitting Multiple Sclerosis
Primary: Change in T Cells Status (Decrease or Increase) at Month 48 (FAS) — -23.7; -1.2; 22.2; -37.2 percentage of parent population — p=< 0.0001
Japanese Encephalitis
Primary: Number and Percentage of Subjects With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 14; 243; 233; 24 Participants
Fever After Vaccination · Fever · Febrile Seizure
Primary: Number of Participants With Fever Following Vaccination — 8; 10 Participants — p=0.7588
Nephrotic Syndrome
Primary: Remission Rate — 34; 13 Participants — p=0.001
Anesthesia, Local
Primary: Mean Time to Pulpal Response After Mandibular Molar Anesthesia — 100; 106 minutes
Bone; Disorder, Development and Growth
Primary: Changes in Insulin-like Growth Factor-1 (IGF-1), IGF Binding Proteins (IGFBP-1, IGFBP-3), and Acid Labile Subunit (ALS) — 220.6; 228.7; 197.1; 221.4 ng/mL
Transfusion-dependent Hemachromatosis · Thalassemia Major · Sickle Cell Disease
Primary: Area Under the Curve of Deferasirox After a Dose of 35 mg/kg — 479.59; 1123.11 micromole/liter*hour — p=<.001
Chronic Hypertension in Pregnancy
Primary: Area Under the Curve for Amlodipine in the Maternal Serum — 53.4 (hr*ng)/mL
Rhinitis, Allergic, Perennial and Seasonal · Rhinitis, Allergic
Primary: Mean Change From Baseline in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over the First 2 Weeks Treatment Period — -1.95; -3.18; -3.28 Scores on a scale…
Bronchospasm · Activity/Exercise Induced Bronchospasm
Primary: Maximal Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Following Exercise Challenge at Week 4 — -9.5; -12.7 Percent change — p=0.021
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — -0.6982; -0.9335 percentage of glycated hemoglobin — p=0.0001
Circumcision, Male
Primary: Intraoperative Duration — 9.5 minutes
Suicidal Ideation
Primary: Perimenstrual Change in Self-Injurious Thoughts and Behaviors Interview (SITBI) Suicidal Ideation Score — -.05; .35 units on a scale — p=.012
Hepatitis B
Primary: Anti-Hepatitis B Surface (Anti-HBs) Antibody Concentrations — 1975.7 mIU/mL
Metabolic Syndrome X
Primary: Plasminogen Activator Inhibitor-1 (PAI-1) Levels — 41.5; 42.9 ng/ml